Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9874755 | 0.85 | POLB (0.62) | POLBSMN1; SMN2ALDH1A1MAPK1RECQL | |
| SCHEMBL31745160 | 0.84 | POLB (0.61) | POLBSMN1; SMN2ALDH1A1MAPK1RECQL | |
| SCHEMBL10744735 | 0.84 | POLB (0.61) | POLBSMN1; SMN2ALDH1A1MAPK1RECQL | |
| SCHEMBL10743454 | 0.82 | POLB (0.60) | POLBSMN1; SMN2ALDH1A1MAPK1RECQL | |
| SCHEMBL10588005 | 0.75 | LMNA (0.55) | POLBSMN1; SMN2ALDH1A1MAPK1RECQL | |
| SCHEMBL14825070 | 0.75 | POLB (1.00) | POLBSMN1; SMN2ALDH1A1MAPK1RECQL | |
| SCHEMBL31647297 | 0.74 | ALDH1A1 (0.51) | POLBSMN1; SMN2ALDH1A1RECQLKDM4E | |
| SCHEMBL2215224 | 0.74 | ALDH1A1 (0.51) | POLBSMN1; SMN2ALDH1A1MAPK1RECQL | |
| SCHEMBL2312662 | 0.74 | ALDH1A1 (0.43) | POLBSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL5010738 | 0.72 | SMN1; SMN2 (1.00) | POLBSMN1; SMN2ALDH1A1RECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | POLB 482/4885SMN1; SMN2 33/4885ALDH1A1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.